SNG-12
SNG-12, also known as Synapsinae, is a glycine transporter 1 (GlyT1) inhibitor, or a glycine reuptake inhibitor, which is under development for the treatment of psychotic disorders, dementia, depressive disorders, and suicidal ideation.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
SNG-12, also known as Synapsinae, is a glycine transporter 1 (GlyT1) inhibitor, or a glycine reuptake inhibitor, which is under development for the treatment of psychotic disorders, dementia, depressive disorders, and suicidal ideation. As of September 2022, it is in phase 3 clinical trials for depressive disorders and suicidal ideation and is in phase 2 clinical rials for psychotic disorders and dementia.
The drug is under development by SyneuRx. It is described as a small molecule, but its chemical structure does not appear to have been disclosed.
See also
Bitopertin Iclepertin Tilapertin
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372046786 under CC BY-SA 4.0; modifications have been made.